Zafemy Patch
Product Images NDC 65162-358

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Zafemy (NDC 65162-358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Where To Put Patch (Zafemy Norelgestromin And Ethinyl Estradiol Transd 1)

Illustrations showing application of ZAFEMY (Norelgestromin and Ethinyl Estradiol) transdermal patch on various body sites including the upper arm, lower abdomen, buttocks, and upper back.*

FDA Label Image

Figure 5 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 10)

A line graph showing Ethinyl Estradiol (EE) concentration in pg/mL over time in hours (h). The graph compares EE concentration changes during Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3, spanning up to 240 hours. Concentration peaks occur near the earlier hours, with a notable decline after approximately 168 hours.*

FDA Label Image

Figure 6 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 11)

A line graph comparing Norelgestromin (NGMN) concentration over time (hours) between ZAFEMY application to the buttock and an oral contraceptive containing NGMN 250 µg and Ethinyl Estradiol (EE) 35 µg. The graph shows concentration in ng/mL on the y-axis and time in hours on the x-axis, with data points up to 240 hours for ZAFEMY and estimated steady state data for the oral contraceptive at 21 days.*

FDA Label Image

Flow Chart (Zafemy Norelgestromin And Ethinyl Estradiol Transd 12)

A line graph comparing Ethinyl Estradiol (EE) concentration (pg/mL) over time (hours) for ZAFEMY transdermal patch applied to the buttock versus an oral contraceptive (NGM 250 µg EE 35 µg). The graph shows EE concentrations on the y-axis and time in hours on the x-axis with data points indicating concentration changes and estimated steady state data based on day 21 for the oral contraceptive.*

FDA Label Image

Calendar (Zafemy Norelgestromin And Ethinyl Estradiol Transd 13)

An illustration showing a vertical scale of pregnancy rates per 100 women per year from fewer to more pregnancies. It categorizes birth control methods by effectiveness, listing implants, injections, intrauterine devices, and sterilization at the most effective end; birth control pills, skin patch, and vaginal rings with hormones next; condoms and diaphragm in the middle; and no sex during fertile days, spermicide, and withdrawal lower. The least effective method listed is no birth control.*

FDA Label Image

Patient Information Graph (Zafemy Norelgestromin And Ethinyl Estradiol Transd 14)

An instructional calendar diagram illustrating a 4-week schedule for a transdermal patch regimen. It shows continuous use of a patch on Day 1 (Week 1), Day 8 (Week 2), and Day 15 (Week 3) with arrows indicating ongoing use. Week 4 (Day 22) is marked with 'NO PATCH,' indicating no patch application during that period.*

FDA Label Image

Figure A (Zafemy Norelgestromin And Ethinyl Estradiol Transd 15)

A horizontal bar chart comparing the estimated number of women with a blood clot per 10,000 woman-years across four groups: Non-CHC users non-pregnant, CHC users, pregnant women, and postpartum women (12 weeks only). The chart displays blood clot ranges from 1 to 65, with postpartum women having the highest risk range shown.*

FDA Label Image

Figure B (Zafemy Norelgestromin And Ethinyl Estradiol Transd 16)

An illustration showing hands peeling a protective backing off a transdermal patch, demonstrating the removal process prior to application. The image highlights the patch preparation step for use.*

FDA Label Image

Where To Put Patch (Zafemy Norelgestromin And Ethinyl Estradiol Transd 17)

ZAFEMY transdermal patch shown being held between thumb and forefinger. The patch is square with rounded corners and beige in color. The image focuses on the patch's size and appearance without visible text or markings.*

FDA Label Image

Usage Illustration 1 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 18)

Illustrations showing the application of ZAFEMY transdermal patches on different areas of the body including the upper arm, lower abdomen, buttocks, and back shoulder area. The images demonstrate suitable placement sites for the patch on adult skin.*

FDA Label Image

Usage Illustration 2 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 19)

An illustration showing two hands applying a rectangular transdermal patch to the skin. The image demonstrates the method of use for a patch-type medication, likely representing the application instructions for the ZAFEMY transdermal patch containing Norelgestromin and Ethinyl Estradiol.*

FDA Label Image

Usage Illustration 1 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 2)

An instructional illustration showing two hands applying a ZAFEMY transdermal patch to the skin, demonstrating the correct method for patch placement and application.*

FDA Label Image

Usage Illustration 3 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 20)

Illustration showing hands applying a ZAFEMY transdermal patch to the skin. The patch is square-shaped with a protective backing being peeled off, demonstrating the proper handling and application method for this Norelgestromin and Ethinyl Estradiol contraceptive patch by Amneal Pharmaceuticals LLC.*

FDA Label Image

Usage Illustration 4 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 21)

An instructional image showing hands applying a ZAFEMY transdermal patch to the skin. The image demonstrates the patch application process for the Norelgestromin and Ethinyl Estradiol combination hormone therapy.*

FDA Label Image

Pouch (Zafemy Norelgestromin And Ethinyl Estradiol Transd 22)

An image showing a transdermal patch being applied to the lower abdomen by a person's hands, illustrating the use of a contraceptive patch like ZAFEMY containing Norelgestromin and Ethinyl Estradiol.*

FDA Label Image

Carton (Zafemy Norelgestromin And Ethinyl Estradiol Transd 23)

ZAFEMY patch label showing the transdermal system containing Norelgestromin and Ethinyl Estradiol with strengths of 150 mcg and 35 mcg per day respectively. The label includes usage instructions, lot number and expiration date markings, storage directions, and warnings. Distributed by Amneal Pharmaceuticals LLC. The label features the product NDC 65162-358-01 and emphasizes that used patches should not be flushed down the toilet.*

FDA Label Image

Zafemy Norelgestromin And Ethinyl Estradiol Transd 24

Packaging label for ZAFEMY 150/35 mcg per day transdermal patch containing norelgestromin and ethinyl estradiol. The label shows the product name, active ingredients, strength, dosage form as transdermal system, and highlights that the package contains 3 transdermal systems. Distributed by Amneal Pharmaceuticals LLC with storage and usage instructions included on the label.*

FDA Label Image

Usage Illustration 2 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 3)

An image of hands holding a transdermal patch, with one hand peeling back the protective liner, demonstrating the preparation of a ZAFEMY transdermal patch for application.*

FDA Label Image

Usage Illustration 3 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 4)

An instructional illustration showing the application of a transdermal patch on a person's skin, focusing on the hand placing the patch onto the body. The image relates to the use of a dosing patch, likely for medication delivery through the skin.*

FDA Label Image

Usage Illustration 4 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 5)

Illustration showing a person applying a transdermal patch to the lower abdomen area. The patch appears small and rectangular and is being placed on bare skin using both hands.*

FDA Label Image

Figure 2 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 6)

A horizontal bar chart depicting the number of women with a blood clot out of 10,000 woman-years across four categories: Non-CHC users who are non-pregnant, CHC users, pregnant women, and postpartum women up to 12 weeks. The chart shows ranges for each category, with postpartum women having the highest range (40 to 65), followed by pregnant women (5 to 20), CHC users (3 to 12), and non-CHC non-pregnant users with the lowest (1 to 5).*

FDA Label Image

Structural Formula (Zafemy Norelgestromin And Ethinyl Estradiol Transd 7)

A forest plot depicting the risk of breast cancer associated with combined oral contraceptive use from various studies conducted between 2002 and 2017. The horizontal axis represents the effect estimate (Odds Ratio/Relative Risk) ranging from -1.5 to 2. Data points with confidence intervals are shown for both 'ever use' and 'current use' categories across multiple cohort studies, illustrating varying estimates around the reference value of 1.0.*

FDA Label Image

Figure 3 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 8)

Chemical structures of the active ingredients Norelgestromin and Ethinyl Estradiol, shown as molecular diagrams with labeled bonds and functional groups.*

FDA Label Image

Figure 4 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 9)

A line graph depicting NGMN concentration (ng/mL) over time (hours) for different cycles and weeks of ZAFEMY transdermal patch use. The graph compares Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3, showing concentration trends from 0 to 240 hours.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.